Compare · EBS vs JNJ
EBS vs JNJ
Side-by-side comparison of Emergent BioSolutions Inc. (EBS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EBS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $558.86B, about 1353.9x EBS ($412.8M).
- Over the past year, EBS is up 23.3% and JNJ is up 49.6% - JNJ leads by 26.3 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 4 for EBS).
- JNJ has more recent analyst coverage (25 ratings vs 14 for EBS).
- Company
- Emergent BioSolutions Inc.
- Johnson & Johnson
- Price
- $8.00-0.87%
- $232.15-0.24%
- Market cap
- $412.8M
- $558.86B
- 1M return
- -12.47%
- +4.36%
- 1Y return
- +23.27%
- +49.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2006
- News (4w)
- 4
- 8
- Recent ratings
- 14
- 25
Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest EBS
- Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
- Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
- Emergent BioSolutions to Participate in Upcoming Investor Conferences
- Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
- Director Dayal Sujata Tyagi was granted 25,344 shares and sold $115,610 worth of shares (13,761 units at $8.40) as part of a pre-agreed trading plan, increasing direct ownership by 13% to 100,563 units (SEC Form 4) (withholding obligation)
- Director Degolyer Donald W was granted 25,344 shares and sold $129,994 worth of shares (15,481 units at $8.40) as part of a pre-agreed trading plan, increasing direct ownership by 8% to 129,721 units (SEC Form 4) (withholding obligation)
- Director Katkin Keith was granted 25,344 shares and sold $128,183 worth of shares (15,481 units at $8.28) as part of a pre-agreed trading plan, increasing direct ownership by 11% to 96,294 units (SEC Form 4) (withholding tax)
- Director White Marvin L was granted 25,344 shares, increasing direct ownership by 29% to 113,839 units (SEC Form 4)
- Director Fowler John D Jr was granted 25,344 shares, increasing direct ownership by 506% to 30,350 units (SEC Form 4)
- Director Richard Ronald was granted 25,344 shares, increasing direct ownership by 26% to 123,761 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research